Meeting
2016 ASCO Annual Meeting
Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.
Presenter
David Michael Woods, PhD
NYU Langone Medical Center2
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3008)
DOI
10.1200/JCO.2016.34.15_suppl.3008
Abstract #
3008
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.
Speaker: Marie-Andree Forget, PhD
Videos & Slides
2023 ASCO Annual Meeting
Clinical Germline and Somatic Sequencing: Causation Versus Association
Speaker: Stacy W. Gray, MD
Speaker: Panel Discussion
Videos & Slides
2021 ASCO Annual Meeting
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.
Speaker: Paolo Antonio Ascierto, MD